Health Care · Pharmaceutical Preparations

KURA Kura Oncology, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1422143164 filings
Russell 2000

KURA at a glance

Kura Oncology, Inc. (KURA, SEC CIK 1422143) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Kura Oncology, Inc. (KURA) reported revenue of $67.5 million (up 25.2% from FY2024) and a net loss of $278.7 million. Diluted EPS was -$3.18.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Kura Oncology, Inc. (KURA) shares worth $389.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Powl Brian T. on November 19, 2026 of 448 shares at $7.27 per share.
  • In the last 90 days, KURA insiders reported 5 open-market purchases ($4.2M) and 19 open-market sales ($1.9M) on Form 4, a net purchase of $2.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$67.5M
+25.2% vs prior year
Insiders · 90 days
5 buys · 19 sells
Net +$2.3M
13F holders
27 funds
$389.9M · +0 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $22.8M, versus $20.8M collaboration revenue last year, with $13.9M KOMZIFTI product revenue
  • Collaboration revenue $8.9M, down $11.8M year over year from $20.8M
  • R&D expenses $66.9M, down from $67.9M, while SG&A declined to $30.2M from $32.8M
  • Cash, cash equivalents and short-term investments $492.1M at September 30, 2026, sufficient to fund operations into 2028
  • Net cash used in operating activities $202.8M, up from $181.3M, while ATM proceeds totaled $31.5M
  • Outlook: R&D and SG&A expected to increase, with additional financing required and Phase 3 topline results anticipated in 2028

Risk Factors

  • Newly added commercialization risk: limited experience marketing KOMZIFTI, triggered by its first commercial launch as the company’s first approved product
  • Most materially updated regulatory risk: FDA post-approval commitments include pediatric, long-term safety, renal/hepatic impairment, drug-interaction and companion-diagnostic studies
  • New compliance exposure: healthcare fraud and abuse laws, including Anti-Kickback Statute, False Claims Act and Sunshine Act requirements
  • Near-term market risk: KOMZIFTI competes with FDA-approved REVUFORJ and established AML therapies
  • Financial risk: continued losses and potential need for substantial additional capital, creating dilution or operating restrictions

AI summary of the KURA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026 announced
  • Corporate update accompanies the earnings release

Item EX-99.1: Item EX-99.1

  • KOMZIFTI revenue $13.9M, up 53% sequentially, with new patient starts up 30% and prescriptions up 65%
  • Majority share of new patient starts supports commercial momentum in R/R NPM1-mutated AML
Filed Sep 9, 2026Full analysis →

Item 8.01: Other Events

  • Caspian raised $50.0M in Series A financing, funding cardiometabolic development outside Kura’s core oncology focus
  • Kura invested $4.3M and retains approximately 49.2% ownership, preserving substantial economic exposure without majority control
Filed Sep 8, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Jennifer Fulk appointed CFO, principal financial officer and principal accounting officer effective September 8, 2026
  • Replaces Troy E. Wilson as principal financial officer and Thomas Doyle as principal accounting officer

AI summaries of KURA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for KURA

Don't miss the next KURA filing

  • Alerts as it files. A push when KURA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut KURA, by share count.
  • Ask anything. An AI agent that reads every KURA filing and answers with sources.

KURA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Powl Brian T.SellNov 19, 2026$7.27
Powl Brian T.SellNov 17, 2026$7.45
FORD KATHLEENSellNov 17, 2026$7.46
Leoni MollieSellNov 17, 2026$7.45
FORD KATHLEENSellNov 16, 2026$7.44
Powl Brian T.SellNov 16, 2026$7.44
Leoni MollieSellNov 16, 2026$7.44
WILSON TROY EDWARDBuyNov 16, 2026$7.42

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$0$53.9M$67.5M
Operating Income-$165.8M-$193.2M-$303.6M
Net Income-$152.6M-$174.0M-$278.7M
Op. Margin--358.5%-449.9%
Net Margin--322.9%-412.9%
Balance Sheet
Total Assets-$760.2M$738.4M
Equity-$413.6M$174.1M
ROE--42.1%-160.0%
Per Share
EPS$-2.08$-2.02$-3.18
Cash Flow
Operating CF-$134.3M-$64.1M
CapEx-$472K$6.6M

Source: XBRL data in Kura Oncology, Inc. (KURA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate KURA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
KURA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$389.9M
Q2 202627$389.6M
Q1 202627$263.7M
Q4 202524$356.7M
Q3 202525$293.5M
Q2 202526$172.3M
Q1 202523$132.2M
Q4 202419$155.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 198 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

KURA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 17, 2026--
4Nov 16, 2026--
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
4Sep 29, 2026--
4Sep 29, 2026--
4Sep 29, 2026--
4Sep 29, 2026--
4Sep 29, 2026--
4Sep 25, 2026--
4Sep 10, 2026--
8-KSep 9, 2026Analysis-
8-KSep 8, 2026Analysis-
4Aug 24, 2026--
4Aug 24, 2026--
4Aug 21, 2026--
4Aug 17, 2026--
8-KAug 12, 2026Analysis-
10-QAug 12, 2026Analysis

Related Health Care companies

All Health Care →

KURA SEC filings: frequently asked questions

Are KURA insiders buying or selling?

In the last 90 days, Kura Oncology, Inc. (KURA) officers, directors and 10% owners reported 5 open-market purchases worth $4.2 million by 1 insider and 19 open-market sales worth $1.9 million by 6 insiders on Form 4, a net purchase of $2.3 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold KURA stock?

As of September 30, 2026, the largest Kura Oncology, Inc. (KURA) holders among the 13F filers tracked by SignalX were BlackRock ($125.9 million), State Street Corp ($50.4 million), Vanguard Capital Management LLC ($41.8 million), AQR Capital Management ($39.5 million), Renaissance Technologies LLC ($21.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was KURA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Kura Oncology, Inc. (KURA) reported revenue of $67.5 million (up 25.2% from FY2024) and a net loss of $278.7 million. Diluted EPS was -$3.18. The figures come from the XBRL data in the 10-K.

What did KURA report in its latest 8-K?

Kura Oncology, Inc. (KURA) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026 announced.

What are the latest KURA SEC filings?

Kura Oncology, Inc. (KURA) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 19, 2026.

What is KURA's SEC CIK number?

Kura Oncology, Inc. (KURA)'s SEC Central Index Key (CIK) is 1422143. EDGAR lists every KURA filing under that number.

Ask anything about KURA

The research agent reads KURA's filings, financials, insider trades and 13F holders, then answers with sources.